View Clinical Trial (Medical Research Study)
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-84132(Clinical Trial 256971)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Salt Lake City |
|
State:
|
|
UT |
| Zip Code: |
|
84132 |
| Conditions: |
|
Hepatitis C, Chronic |
| Purpose: |
|
This single arm study will provide treatment or re-treatment with PEGASYS as monotherapy or
in combination with ribavirin (Copegus), to patients with chronic hepatitis C (CHC) who have
participated in a previous Roche or Roche partner protocol where access to treatment or
re-treatment was promised or deemed appropriate following completion of the original
protocol ('donor' protocol). Patients who qualify for treatment or re-treatment will begin
PEGASYS monotherapy,at a maximum dose of 180 micrograms weekly, or combination therapy with
Copegus ,800-1200mg daily, as continuation of treatment after the wash-out period defined in
their donor protocol. PEGASYS treatment is not to exceed approved treatment duration of 24
weeks in genotype 2/3 and 48 weeks in genotype non-2/3 with a treatment-free follow up
period of 24 weeks. The anticipated time on study treatment is 3-12 months, and the target
sample size is 100-500 individuals.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- adult patients, >=18 years of age;
- CHC patients with compensated liver disease (Child-Pugh A) who have participated in a
donor protocol where access to treatment or re-treatment with PEGASYS monotherapy or
in combination with Copegus was promised or deemed appropriate after completion of
the donor protocol.
Exclusion Criteria:
- evidence of decompensated liver disease (Child B or C cirrhosis). |
|
|
|
| Study is available at: |
|
Salt Lake City, UT 84132
United States
Primary Contact:
Please reference Study ID Number: NV21928
Email: genentechclinicaltrials@druginfo.com
Phone: 888-662-6728 (U.S. Only) |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 22, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|